Trial of Tocilizumab for Treatment of Severe COVID-19: ARCHITECTS

Summary

The overall objective is to evaluate the clinical efficacy and safety of tocilizumab relative to placebo among approximately 300 hospitalized adult patients who have severe COVID-19. The study will be a 2 arm double blinded comparison between tocilizumab 8 mg/kg and matching placebo IV. The dose may be repeated in 8-12 hours if clinical symptoms worsens, (e.g. increase in oxygen requirements). Participants will be followed for 28 days.

Timeline

Start

2020-06-12

Primary completion

2021-03-31

Completion

2021-03-31

Outcome

Outcome not reported

Stopped: “Per Queen's Regulatory Office, study is terminated or expired.”

Drugs

Indications